Stacks Image 1300

THE REDAPT STUDY

The Neuropsychiatry Unit has seen patients with metabolic disorders in the outpatient clinics for several years for clinical monitoring. We are now involved in a collaborative study with the Metabolic Disease Unit and the Department of Radiology at the Royal Melbourne Hospital called “The Resumption of Dietary control in Adult Phenylketonuria Trial (ReDAPT)”.

Phenylketonuria (PKU) is a an inherited problem of metabolism, where Phenylalanine (Phe) in the diet is not processed properly and accumulates in the brain and body, leading to a range of problems, which if left unchecked in childhood can lead to severe disabilities. Previous research has suggested that difficulties can continue into adulthood and include cognitive and psychological problems.

In the ReDAPT trial, adult patients are asked to recommence a Phe restricted diet. Prior to re-starting the diet, they undergo a preliminary assessment which measures their level of Phe in the blood as well as assessing their psychological and cognitive function. These assessments are repeated at two subsequent time points after the diet is commenced. Data collection is currently occurring for the ReDAPT study.